The Evolution of Sodium-Glucose Co-Transporter-2 Inhibitors in Heart Failure

Sodium-glucose co-transporter-2 (SGLT2) inhibitors have evolved over the years, based on data from several randomized, double-blinded, placebo-controlled clinical trials. Formerly used primarily for blood sugar control in patients with diabetes, they are now used to decrease the risk of hospitalizat...

Descripción completa

Detalles Bibliográficos
Autores principales: Fadiran, Olusayo, Nwabuo, Chike
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
Cardiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8654149/
https://www.ncbi.nlm.nih.gov/pubmed/34925982
http://dx.doi.org/10.7759/cureus.19379

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8654149/
https://www.ncbi.nlm.nih.gov/pubmed/34925982
http://dx.doi.org/10.7759/cureus.19379

Ejemplares similares